Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B. Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers. Clinical Cancer Research 2013, 19: 6633-6643. PMID: 24088734, PMCID: PMC4045641, DOI: 10.1158/1078-0432.ccr-13-0152.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, WesternCarcinoma, Squamous CellCombined Modality TherapyCyclin-Dependent Kinase Inhibitor p16DNA RepairDNA-Binding ProteinsEndonucleasesFemaleHead and Neck NeoplasmsHeLa CellsHumansImmunoprecipitationKaplan-Meier EstimateMaleNeoplasm Recurrence, LocalRetrospective StudiesTissue Array AnalysisTreatment OutcomeConceptsMedian survivalExcision Repair Cross-Complementing Group 1Low ERCC1 expressionSquamous cell headKaplan-Meier curvesSquamous cell carcinomaCisplatin-based therapyLonger median survivalERCC1 protein expressionInitial tumor presentationAdjuvant radiotherapyMultimodality treatmentRecurrent diseaseInitial presentationMultivariable analysisRecurrent cancerTumor presentationCell carcinomaHuman papillomavirusERCC1 expressionNeck cancerSurvival differencesCell headArchival tumorsGroup 1